Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
Recruiting now Phase 3 NCT05568719
Run by Pfizer · for 18 and older · Men
What this study is about
A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
Who can join (things the study team will check)
Inclusion Criteria: -Only participants who received investigational giroctocogene fitelparvovec or fidanacogene eleparvovec and were enrolled in a Pfizer-sponsored study (C0371002, C0371003, C0371005, C3731001, C3731003) are eligible. Exclusion Criteria: -None…
Where this trial is running
- The Regents of the University of California||UC Davis Health, Rancho Cordova, California, United States
- UC Davis Health, Sacramento, California, United States
- UC Davis Ambulatory Care Clinic, Sacramento, California, United States
- UC Davis Hemophilia Treatment Center, Sacramento, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- UCSF Outpatient Hematology Clinic, San Francisco, California, United States
- USF Health Morsani Center For Advanced Healthcare, Tampa, Florida, United States
- The University of South Florida Board of Trustees, Tampa, Florida, United States
- Mississippi Center For Advanced Medicine, Madison, Mississippi, United States
- Cornell University||Joan & Sanford I. Weill Medical College, New York, New York, United States
- Weill Cornell Medical College-New York Presbyterian Hospital, New York, New York, United States
- The Childrens Hospital of Philadelphia Division of Hematology, Philadelphia, Pennsylvania, United States
+ 11 more sites.
Who to contact
Pfizer CT.gov Call Center · 1-800-718-1021 · ClinicalTrials.gov_Inquiries@pfizer.com
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05568719.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.